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Edited by Horst FeldmannAbstract Dosage compensation involves ﬁne-tuning of gene
expression at the level of entire chromosomes. The principles
that assure selective targeting of the male X chromosome in
Drosophila and the mechanism by which transcription levels
are adjusted in a twofold range are still mysterious. We dis-
cuss the prevalent models in the context of recent experimental
observations.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Sexual dimorphism is brought about by diﬀerent sex chro-
mosomes, which are unequally distributed between the sexes.
For example in humans and fruit ﬂies females carry two X
chromosomes, but males have only a single X chromosome
in addition to the gene-poor Y chromosome. Hence, male cells
contain a halved dose of all X-linked genes. The level of X-
linked gene products, however, must be similar in cells of
either sex. A prime principle of gene dosage compensation is
the chromosome-wide adjustment of transcription. The mech-
anisms by which this may be achieved vary largely between dif-
ferent organisms and involve diﬀerent molecular factors.
Whereas female mammals inactivate one of their two X chro-
mosomes in order to approximate the gene dosage of males, C.
elegans hermaphrodites (XX) reduce transcription of each X
by about half. In Drosophila, the male ﬂies increase transcrip-
tion from their single X chromosome about twofold to equal
the expression of the two X chromosomes in females (for
extensive reviews see [1–5]). This adjustment is essential for
male survival. Dosage compensation in ﬂies relies on the integ-
rity of a ribonucleoprotein complex, known as the dosage
compensation complex (DCC). This complex comprises the
male-speciﬁc lethal (MSL) proteins and two non-coding
RNA molecules, roX1 and roX2. Male-speciﬁc expression ofAbbreviations: DCC, dosage compensation complex; MSL, male-spe-
ciﬁc lethal; H4K16, lysine 16 of histone H4
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doi:10.1016/j.febslet.2005.03.050MSL2 leads to enrichment of the DCC on the single X chro-
mosome. The cooperation of structural and enzymatic com-
plex components is necessary for proper function and
targeting. So far, the catalytic activities known to be essential
for the compensation process are the ATPase/helicase activity
of MLE and the histone acetyl transferase activity of MOF.
Accumulation of the DCC on the X chromosome results in in-
creased acetylation of lysine 16 on histone H4. This speciﬁc
chromatin modiﬁcation is thought to be at least in part respon-
sible for elevated X-linked gene expression.
The mechanisms that assure that a fairly global process act-
ing at the level of an entire chromosome leads to rather subtle
(twofold) tuning of transcription are still mysterious. However,
integrating the limited experimental observations into models
has been instructive. Not surprisingly, diﬀerent kinds of mod-
els have been proposed trying to explain the mode of precise
transcription tuning and to describe how the X chromosome
gets exclusively furnished with the DCC. Experimental pro-
gress now allows for the critical evaluation of these models.2. Opposing models for dosage compensation
The prevailing model (Fig. 1, model A) for the compensation
of the X chromosomal genes in males states that the DCC is
directly involved in activating gene expression on the male X
chromosome. It is based on the following observations: (a)
in Drosophila males, the MSL proteins are almost exclusively
located on the X chromosome [4]; (b) H4K16 acetylation fol-
lows the distribution of the MSLs [6]; (c) acetylation of
H4K16 can activate transcription in a chromatin context [7];
(d) the male X chromosome has a more diﬀuse appearance,
reminiscent of reduced chromatin condensation [1]; (e)
knock-down of any of the MSL proteins in males reduces
expression of X chromosomal genes relative to that of autoso-
mal genes and leads to loss of compensation and male lethality
[8,9]. Accordingly, in Drosophila males MSL2 stabilizes and
tethers the DCC to the X chromosome. Concomitant enrich-
ment of H4K16 acetylation results in local chromatin opening
and a twofold increase in transcription, conceivably at the level
of elongation [10]. Reﬂecting its role as a direct modulator of
gene expression, the model implies a ﬂexible and direct associ-
ation of the DCC with active genomic loci [11].
Although the model is straightforward and intuitive, not all
phenomena can be smoothly incorporated and key aspects
have not yet been experimentally veriﬁed. For example, all
MSL proteins (with the exception of MSL2) are present in fe-
male cells as well, albeit some of them at reduced levels, whereblished by Elsevier B.V. All rights reserved.
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Fig. 1. Diﬀerent models for how compensation of the X-linked genes is achieved in order to equalize gene doses between male (XY) and female (XX)
ﬂies. Model A suggests male-speciﬁc assembly of the dosage compensation complex (DCC) that directly activates gene expression on the X. Model B
proposes that compensation of the X is accomplished by a genome-wide increase in transcription that is due to activator imbalance inferred by X
chromosomal monosomy. Tethering of the activators (members of the DCC) onto the male X alleviates the transcription enhancement on the
autosomes. While the expression status in wild type males is the same for both models, MLE mutants (XY mle-) uncover major diﬀerences
characterizing the two hypotheses.
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unexplained issue is how the targeted H4K16 acetylation will
bring about a general and precise twofold elevation of tran-
scription [10]. Increased H4K16 acetylation might induce a
chromosome-wide chromatin decondensation leading to an
elevated transcription in the proper range of magnitude.
Unfortunately, there is no experimental evidence for such an
eﬀect. In vitro, MOF-mediated histone acetylation has been
shown to relieve chromatin-mediated transcriptional repres-
sion [7]. However, the activation observed was much more
than twofold. A precise doubling of transcription is likely a re-
sult of a ﬁne balance between activation and feedback repres-
sion and thus it is possible that DCC harbours repressive
activities in addition to the activating histone acetylation func-
tion, activities that are not yet accounted for by model A. In
general, histone acetylation is involved in gene activation in
all eukaryotes from yeast to man. Surprisingly, acetylation of
H4K16 is an exception to this rule, since in yeast, where its
occurrence has been correlated with gene activity on a gen-
ome-wide scale, it was shown to mark inactive, rather than ac-
tive loci [12]. Accordingly, H4K16ac has been postulated to
prevent binding of transcription factors in silent chromatin re-
gions in yeast. While we appreciate that the language of his-
tone modiﬁcations is modulated by species-speciﬁc dialects
[13], the case of yeast chromatin suggests complex eﬀects of
H4K16 acetylation, which may impact on model building for
dosage compensation in Drosophila.
The most important objection to model A is, however, the
lack of absolute quantiﬁcation of gene expression conﬁrming
the direct involvement of the DCC in compensation of X-
linked genes.Birchler and colleagues have proposed an alternative and
less intuitive model (Fig. 1, model B) that employs a gen-
ome-wide mechanism underlying the compensation of the X
chromosome [14]. Central to this model is the inverse dosage
eﬀect, which can be observed when large chromosomal seg-
ments are rendered aneuploid. Such deletions have been ob-
served to lead to a global increase in gene expression. This
may be explained by a preferential loss of transcriptional
repressors given a higher prevalence of those factors. Thus,
deletion of a chromosomal segment will oﬀset the balance be-
tween global positive and negative regulators, resulting in a
dominance of positive factors. According to Birchler, the X
chromosomal monosomy in males is a special case of an
aneuploidy that did not arise by abrupt deletion, but by the
gradual process of diversiﬁcation of sex chromosomes. The
evolutionary time scales to be considered provided ample
opportunity for co-evolution of compensatory principles that
re-establish the balance of gene expression. According to the
model, loss of one X chromosome in males leads to a global
inverse regulation of gene expression, i.e. to hyperactivation
of all autosomes and the remaining X chromosome due to
a relative preponderance of positive transcription regulators
[14]. In Drosophila metafemales harbouring three X chromo-
somes, the same principle would compensate the increase in
X chromosomal dosis by a general reduction of gene expres-
sion to 2/3 [14]. Although the inverse dosage eﬀect compen-
sated for the aneuploidy of the X chromosome, it obviously
would not allow male survival, since all autosomal gene
expression is doubled relative to that in females (Fig. 1B, cen-
tre panel). In order to counteract autosomal hyperactivation,
Birchler proposes that global activators of transcription, con-
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MSL2/MLE-mediated sequestration to the X chromosome
(Fig. 1B, right panel). Consequently, MOF-mediated histone
acetylation is enriched on the X and gene expression on the
autosomes drops. Now, in order to prevent excessive activa-
tion of X chromosomal target genes, repressive mechanisms
are required to limit gene activation to the twofold eﬀect,
brought about by the inverse dosage eﬀect. Such negative
eﬀectors my reside in the MSL complex itself [14] or involve
other factors, such as the chromatin remodeling ATPase
ISWI [15,16].
Apparently, one of the fundamental diﬀerences between
the models is stipulated by the role of MSL2: whereas in
model A MSL2 and the DCC it organises are directly in-
volved in activation, in model B dosage compensation is
brought about by the inverse dosage eﬀect, which may have
no direct mechanistic connection to the MSL proteins. Here,
MSL2 may function in two distinct ways: ﬁrst, to tether glo-
bal autosomal activators (the other MSL proteins) to the X
chromosome in order to counteract autosomal hyperactiva-
tion, and second, to prevent excessive activation by in-
creased H4K16 acetylation on the X. Accordingly, the
presence of DCC on the X chromosome might not necessar-
ily correlate with activated transcription. A prediction of
model B is that disruption of MSL2 or MLE would result
in a release of activators and an increased autosomal expres-
sion. Under these circumstances X chromosomal expression
would remain unchanged due to the retained inverse dosage
eﬀect. The strongest support for this model stems from
experiments employing absolute quantiﬁcation of gene
expression [14,16]. These measurements demonstrated, for
instance, the predicted absolute increase in autosomal gene
expression upon knockdown of MLE for a number of genes
(Fig. 1, compare the two models in the XY mle-background)
[17]. However, the global nature of the inverse dosage eﬀect
appears to be less robust. Although some genes respond as
predicted in the experiments performed by Birchler and co-
workers [18], a signiﬁcant number of them do not. MSL mu-
tants that should re-establish the inverse dosage eﬀect on the
autosomes by releasing the activators exhibit a rather heter-
ogeneous expression response of autosomal genes. Although
highly suggested by the model, MOF does not appear to
contribute to the compensation of the X by the inverse dos-
age eﬀect: in MOF mutants X chromosomal gene expression
remained unchanged [16]. At this point it remains unclear
why MOF is recruited to the X in order to relieve the in-
verse dosage eﬀect on the autosomes and, most importantly,
why a mof mutation is lethal for males only. An obvious
drawback of the model is, therefore, that the inverse dosage
eﬀect it employs to explain dosage compensation remains
even more mysterious than the phenomenon it tried to ex-
plain. Ockhams razor would ﬁnd ample opportunities for
trimming.
Absolute quantiﬁcation of gene expression as applied by
Birchler and colleagues is an important step towards deﬁning
the actual compensation process and testing models. How-
ever, care has to be taken regarding the specimen analyzed.
The MSL mutant phenotype of embryos or larvae could be
compromised to various extend by maternal contribution of
MSL proteins and by secondary eﬀects on gene expression
in dying larvae. Crucial for the validation of any model will
be to deﬁne the functional contribution of H4K16 acetyla-tion to the compensation process as the simple rule ‘‘histone
acetylation equals gene activation’’ turns out to be obsolete
[12].3. Recruitment of DCC to the X chromosome: Models in
transition
The two contrasting models for how the DCC functions in
dosage compensation discussed above have diﬀerent implica-
tions for the importance of the targeting and distribution of
the complex. Model A implies that the correct distribution of
the DCC is vital for its function in up-regulating transcription,
whereas in model B the precise location of the complex may
not be so important. A longstanding model for how localisa-
tion of the DCC to the X is achieved involves primary recog-
nition of speciﬁc sites (entry sites) followed by distribution
along the chromosome by spreading in cis from these sites
to less deﬁned chromatin [19]. Recent observations have chal-
lenged this entry-site model and led to the proposition of an
alternative model involving a larger number of speciﬁc sites
of varying aﬃnities [4,20,21]. Both models are based on obser-
vations using salivary gland polytene chromosomes where the
distribution of the DCC can be easily visualised by immuno-
staining (Fig. 2, top pictures). In wild type male nuclei, the
complex binds mainly to interbands in a characteristic pattern
[23].
The entry site model was originally based on the character-
isation of the two ﬁrst speciﬁc binding sites for the DCC found
within the roX1 and roX2 genes. The roX genes are part of a
relatively small set of DCC binding sites that is observed in fe-
males expressing MSL2 and mutant for msl3, mle or mof [4].
This very visually suggested the presence of a special type of
binding site, proposed to be the initial sites of recruitment,
from which the complex would subsequently spread to cover
the chromosome. Accordingly, these site were termed chroma-
tin entry sites (CES) [19]. Detailed studies of the roX1 and
roX2 sites provided convincing evidence in favour of the model
[22–24]. When the roX genes were inserted on autosomes via
P-element transformation, the DCC was recruited to the inser-
tion site. Importantly, the DCC was occasionally seen to
spread to neighbouring, autosomal interbands in a pattern
reminiscent of that seen on the X, suggesting that this recruit-
ment and spreading mirrored the real mechanism for targeting
and distribution of the DCC. The entry site model (illustrated
in Fig. 2a) therefore predicts that the CES are the only speciﬁc
recruitment sites for the DCC. Binding to an entry site would
be a prerequisite for the occupancy of secondary, non-speciﬁc
sites in the vicinity, a process that has been referred to as epi-
genetic spreading [5,23]. It has been proposed that these sec-
ondary sites may represent sites of active transcription where
the complex is required to implement dosage compensation.
Using transposable elements on the X that contain UAS se-
quences, it has been demonstrated that the DCC can be re-
cruited to these elements upon activation of transcription by
Gal4 [11].
Two aspects of the entry site model have been questioned
by recent results. Firstly, on several occasions insertion of X
chromosomal sequences lacking a CES still led to recruitment
of the DCC to autosomes in wild type males ([21], IKD unpub-
lished). In addition, several large translocations from the X to
Fig. 2. Sequential occupancy of the X chromosome might employ diﬀerent ways of complex distribution. Depicted are two Drosophila polytene
chromosome stainings for MSL1 at low (upper panel) or high (lower panel) concentration of complex. The way the complexes target new bands
(long-range distribution, a–c) and the chromosome binding within a band (short-range distribution, d–f) are controversially discussed.
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DCC [20]. These observations demonstrate that DCC recruit-
ment is not restricted to a small number of dedicated entry
sites.
The second aspect of the entry site model that has been
challenged by recent data is whether spreading actually occurs
as part of the mechanism for distribution of the DCC over the
X chromosome. Extensive spreading from autosomal roX
genes, which depended on the transcription of the roX
RNA, the abundance of DCC [27] and was particularly evident
if the number of roX genes was reduced [25,26], turns out to be
the exception rather than the rule. The third CES to be de-
scribed, 18D, was found to induce only minimal spreading in
rare cases [21]. Importantly, when parts of autosomes gettranslocated to the X, spreading of the DCC into autosomal
sequences does not occur, even if the translocations lie close
to entry sites, including roX genes [20,21]. This suggests that
spreading is not the prevailing mechanism for DCC distribu-
tion and that the X chromosome harbours recognition ele-
ments in addition to the known entry sites.
The observations described above have led to a revised model
for the targeting and distribution of the DCC, which we refer
to as the aﬃnities model (Fig. 2b) [4,20,21]. This model as-
sumes that most, if not all, binding sites for the DCC are spe-
ciﬁc, but of varying aﬃnities for the DCC. Accordingly, one
major determinant of recruitment is the concentration of intact
DCC in a nucleus. Studies using females expressing varying
levels of MSL2 support this prediction as when complex levels
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in the msl mutant backgrounds [27]. In this scenario, the entry
sites are not special recruitment sites, but merely represent the
highest aﬃnity sites. Partial and/or complete complexes would
bind ﬁrst to these high aﬃnity sites, and as complex levels rise,
moderate and lower aﬃnity sites would get ﬁlled until the com-
plex is covering the X chromosome. Lowering the amount of
DCC in general or depletion of a DCC component will still
allow interaction with high aﬃnity sites, but leave sites of
lower aﬃnity unbound. Thus a major diﬀerence to the entry
site model is that binding to lower aﬃnity sites does not de-
pend on prior binding to a nearby CES, which explains why
many X derived sequences lacking entry sites can recruit the
complex.
A model based purely on aﬃnities predicts that any part of
the X, which is normally bound by the DCC, would be able to
recruit the complex to an autosomal position in wild type
males. However, early attempts at recruiting the DCC to auto-
somal insertions of dosage compensated genes such as white
and yellow failed. In fact a transposable element carrying a
179 kb segment between white and roughest, which is bound
by the complex on the X, failed to recruit the DCC to its auto-
somal location [17]. It is therefore probable that many of the
proposed low aﬃnity sites proﬁt from high local concentra-
tions of DCC on the X chromosome and are not able to recruit
the complex if moved out of this context. Under those circum-
stances, the term spreading may therefore be used to describe
how low aﬃnity sites beneﬁt from the presence of higher aﬃn-
ity sites that increase the local concentration of complex (Fig.
2c). This might explain why the roX genes can induce extensive
spreading on autosomes when they are the only source of
RNA or when the levels of complex are increased. The very
high local concentrations of DCC generated on the autosomal
insertion site in this case would allow recruitment to such low
aﬃnity sites on autosomes. The recruitment of the DCC to
sites of active transcription [11] may suggest that low aﬃnity
sites could be deﬁned by features other than DNA sequence
alone, such as the presence of active marks on chromatin or
the transcription machinery itself.
As previously mentioned, the models described above are
entirely based on studies using polytene chromosomes as these
provide a way of visualizing the global distribution of chroma-
tin-associated proteins. However, the limited resolution means
that we know little about how the DCC proteins are distrib-
uted within what we see as a ﬂuorescent band on polytenes.
Fig. 2 (models d–f) illustrates some of the various possibilities
for short-range distribution. Each band of DCC signal could
represent a single binding site for the complex. In support of
this, single transcription factor binding sites give a similar sig-
nal when visualised by immunoﬂuorescence [28]. On the other
hand, it is possible that each band contains many speciﬁc
binding sites for the complex. Analysis of the 18D entry site
indicates that this site may be made up of multiple elements
distributed over up to 8.8 kb [21]. Finally, it is also conceivable
that each band results from several binding events: one pri-
mary, sequence-speciﬁc binding and additional contacts within
the domain with no sequence deﬁnition. In this context, the
term spreading may be used to indicate an equilibration of
chromatin binding within a domain, which may be limited
by domain boundaries. Alternatively, the distribution of
DCC within a band may be determined by active chromatin it-
self. Such a scenario gains support from mapping of the distri-bution of the H4K16 acetylation mark by chromatin
immunoprecipitation, which correlated the acetylation mark
with active transcription units [10].4. Outlook
In order to resolve the issues of how dosage compensation is
achieved on a transcriptional level and what determines the
distribution of the DCC, further molecular studies will be
essential. Regarding the mode of hyperactivation, applying
absolute quantiﬁcation of gene expression to cell systems in
which the DCC can be knocked down by RNA interference
will reveal the actual phenotype of mutant ﬂies at the gene le-
vel. Identiﬁcation and characterisation of more DCC binding
sites that are not related to the roX genes should ﬁnally lead
to a molecular explanation for their sequential occupancy.
Increasing the resolution of mapping experiments by applying
chromatin IP will help to uncover signiﬁcant correlations be-
tween DCC binding, histone acetylation and compensated
gene expression. The comprehensive collection of molecular
data will hopefully facilitate the integration of the various
models discussed here into one model for dosage compensa-
tion in ﬂies.
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